国内部分PDE5抑制剂上市情况(不完全统计)20年磨一剑80亿市场再添新军目前,我国ED一线治疗方案主要是口服药物治疗,临床上常用的药物是磷酸二酯酶5(PDE-5)抑制剂,西地那非、他达拉非、伐地那非、阿伐那非已成为国内市场畅销的抗ED药物。米内网数据显示,近年来中国三大终端六大市场抗ED化药销售额呈逐年上涨态势,2023-2024年均超过80亿元。从细分终端看,零售药店(城市实体药店+网上药店)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.